
    
      The objective of the trial is to evaluate the safety and efficacy of JMT101 combined with
      EGFR-TKIs (afatinib or osimertinib) in patients with locally advanced or metastatic NSCLC
      with EGFR exon 20 insertion mutations.

      This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study,
      and Stage II was a dose expansion study.
    
  